

## USE OF CILIARY NEUROTROPHIC FACTOR

*58  
a  
b6  
b7c  
b7d  
b7e  
b7f  
b7g  
b7h  
b7i  
b7j  
b7k  
b7l  
b7m  
b7n  
b7o  
b7p  
b7q  
b7r  
b7s  
b7t  
b7u  
b7v  
b7w  
b7x  
b7y  
b7z*

This application is a continuation-in-part of ~~United States Patent Application Serial No. 09/454,380 filed December 3, 1999 which is a continuation of United States Patent Application Serial No. 09/373,834 filed August 13, 1999 which is a continuation of United States Patent Application Serial No. 09/031,693 filed February 27, 1998 which is a continuation -in-part of United States Patent Application Serial No. 08/645,107 filed May 13, 1996, which is a continuation-in-part of 08/308,736 filed September 14, 1994, which issued as United States Patent No. 5,846,935 on December 8, 1998, which is a continuation-in-part of United States Patent Application Serial No. 07/959,284 filed October 9, 1992 entitled "Ciliary Neurotrophic Factors" which issued as United States Patent No. 5,349,056 on September 20, 1994.~~ Throughout this application, various patent and publications are referenced. Those patents and publications are hereby incorporated by reference in their entireties, into this application.

### BACKGROUND OF THE INVENTION

The present invention relates to ciliary neurotrophic factor (CNTF) and CNTF-related polypeptides useful for the treatment of neurological diseases, obesity and other diseases or disorders.

CNTF is a protein that is required for the survival of embryonic chick ciliary ganglion neurons in vitro (Manthorpe et al., 1980, *J. Neurochem.* 34:69-75). The ciliary ganglion is anatomically located within the orbital cavity, lying between the lateral rectus and the sheath of the optic nerve; it receives parasympathetic nerve fibers from the oculomotor nerve which innervates the ciliary muscle and sphincter pupillae.

Over the past decade, a number of biological effects have been ascribed to CNTF in addition to its ability to support the survival of ciliary ganglion neurons. CNTF is

believed to induce the differentiation of bipotential glial progenitor cells in the perinatal rat optic nerve and brain (Hughes et al., 1988, *Nature* 335:70-73).

Furthermore, it has been observed to promote the survival of embryonic chick dorsal root ganglion sensory neurons (Skaper and Varon, 1986, *Brain Res.* 389:39-46).

5 In addition, CNTF supports the survival and differentiation of motor neurons, hippocampal neurons and presynaptic spinal cord neurons (Sendtner, et al., 1990, *Nature* 345: 440-441; Ip, et al. 1991, *J. Neurosci.* 11:3124-3134; Blottner, et al. 1989, *Neurosci. Lett.* 105:316-320).

10 CNTF has been cloned and synthesized in bacterial expression systems, as described by Masiakowski, et al., 1991, *J. Neurosci.* 5:1003-1012 and in International Publication No. WO 91/04316, published on April 4, 1991, both of which are incorporated by reference in their entirety herein.

20 In addition to human CNTF, the corresponding rat (Stöckli et al., 1989, *Nature* 342:920-923), and rabbit (Lin et al., 1989, *J. Biol. Chem.* 265:8942-8947) genes have been cloned and found to encode a protein of 200 amino acids, which share about 80% sequence identity with the human gene. Both the human and rat recombinant proteins have been expressed at exceptionally high levels (up to 70% of total protein) and purified to near homogeneity.

25 Despite their structural and functional similarity, recombinant human and rat CNTF differ in several respects. The biological activity of recombinant rat CNTF in supporting survival and neurite outgrowth from embryonic chick ciliary neurons in culture is four times better than that of recombinant human CNTF (rHCNTF) (Masiakowski et al., 1991, *J. Neurochem.* 57:1003-1012). Further, rat CNTF has a higher affinity for the human CNTF receptor than does human CNTF (Davis et al., 1991, *Science* 253: 59-63).

30 A surprising difference in the physical properties of human and rat CNTF, which are identical in size, is their different mobility on SDS gels. This difference in

behavior suggests the presence of an unusual structural feature in one of the two molecules that persists even in the denatured state (Masiakowski et al., 1991, *J. Neurochem.* **52**:1003-1012).

5 To better understand the physical, biochemical and pharmacological properties of rHCNTF, applicants undertook rational mutagenesis of the human and rat CNTF genes based on the different biological and physical properties of their corresponding recombinant proteins (See Masiakowski, P., et al., 1991, *J. Neurochem.*, 57:1003 1012).  
10 Mutagenesis by genetic engineering has been used extensively in order to elucidate the structural organization of functional domains of recombinant proteins. Several different approaches have been described in the literature for carrying out deletion or substitution mutagenesis. The most successful appear to be alanine scanning mutagenesis (Cunningham and Wells 1989, *Science* 244: 1081-1085) and homolog-scanning mutagenesis (Cunningham et al., 1989, *Science* 243:1330-1336). These approaches helped identify the receptor binding domains of growth hormone and create hybrid proteins with altered binding properties to their cognate receptors.

Applicants have found that the nature of the amino acid at position 63 could greatly enhance the affinity of human CNTF for soluble CNTFR $\alpha$  and its biological potency *in vitro* (Panayotatos, N., et al., J. Biol. Chem., 1993, 268:19000-19003; Panayotatos, N., et al., Biochemistry, 1994, 33: 5813-5818).

The CNTF receptor complex contains three proteins: a specificity determining  $\alpha$  component that directly binds to CNTF, as well as two signal transducing  $\beta$  components (LIFR $\beta$  and gp130) that cannot bind CNTF on their own, but are required to initiate signaling in response to CNTF. The  $\beta$  component of the CNTFR complex is more widely distributed throughout the body than the  $\alpha$  component. The 3 components of the CNTFR complex are normally unassociated on the cell surface; CNTF induces the stepwise assembly of a complete receptor complex by first binding to CNTFR  $\alpha$ , then engaging gp130, and finally recruiting LIFR $\beta$ . When this

final step in receptor assembly occurs (heterodimerization of the  $\beta$  components), intracellular signaling is initiated by activating non-receptor tyrosine kinases (JAK kinases) associated with the  $\beta$  components. JAK kinases respond by phosphorylating each other and also tyrosine residues on the receptor cytoplasmic 5 domains, creating phosphotyrosine docking sites for the Src homology 2 domains of STAT proteins. After their phosphorylation, bound STAT proteins dissociate from the receptor, dimerize, and translocate to the nucleus where they bind DNA and activate transcription (reviews: Frank, D. and Greenberg, M. (1996) Perspectives on Developmental Neurobiology 4: 3-18; Stahl, N. and Yancopoulos, G. (1997) Growth 10 factors and cytokines in health and disease 2B, 777-809). Axokine is a mutant CNTF molecule with improved physical and chemical properties, which retains the ability to interact with and activate the CNTF receptor. (Panayotatos, N., et al. (1993) J. Biol. Chem. 268: 19000-19003).

0  
15  
0  
0  
0  
0  
0  
20

Leptin, the product of the ob gene, is secreted by adipocytes and functions as a peripheral signal to the brain to regulate food intake and energy metabolism (Zhang, Y., et al. (1994) Nature 372: 425-431). Interestingly, leptin receptor (OB-R), a single membrane-spanning receptor, has considerable sequence similarities to gp130 (Tartaglia, L., et al. (1995) Cell 83: 1263-1271). Both CNTF and leptin each signals through the JAK/STAT pathway (Baumann, H., et al. (1996) Proc. Natl. Acad. Sci. USA 93: 8374-8378; Ghilardi, N., et al. (1996) Proc. Natl. Acad. Sci. USA 93: 6231-6235). Systemic administration of both CNTF and leptin results in induction of 11 (Gloaguen, I., et al. (1997) Proc. Natl. Acad. Sci. USA 94: 6456-6461) and STAT3 (Vaisse, C., et al. (1996) Nature Gen. 14: 95-97) in the hypothalamic satiety center, 25 indicating their roles in the regulation of body weight and feeding behavior. Indeed, in a clinical trial testing the use of CNTF for treating ALS, it was found that administration of CNTF to humans reduced food intake and resulted in weight loss (Group, A. C. T. S. (1996) Neurology 46:1244-1249.).

## SUMMARY OF THE INVENTION

An object of the present invention is to provide CNTF and CNTF-related proteins, collectively referred to herein as CNTF proteins, for the treatment of diseases or 5 disorders including, but not limited to, obesity and diabetes.

A further object of the present invention is to provide a method for administering CNTF or CNTF-related proteins and maintaining biological activity. A preferred embodiment of this invention is the administration of CNTF or a CNTF related 10 protein to the nasal or respiratory system of a mammal to produce an increase in the level of the protein in the systemic blood circulation of the mammal. A particularly preferred embodiment comprises the administration of the modified CNTF molecule, designated herein as AX-15, to the nasal passages of a patient for the treatment of obesity or diabetes.

## BRIEF DESCRIPTION OF THE FIGURES

Subj 28  
5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1215  
1220  
1225  
1230  
1235  
1240  
1245  
1250  
1255  
1260  
1265  
1270  
1275  
1280  
1285  
1290  
1295  
1300  
1305  
1310  
1315  
1320  
1325  
1330  
1335  
1340  
1345  
1350  
1355  
1360  
1365  
1370  
1375  
1380  
1385  
1390  
1395  
1400  
1405  
1410  
1415  
1420  
1425  
1430  
1435  
1440  
1445  
1450  
1455  
1460  
1465  
1470  
1475  
1480  
1485  
1490  
1495  
1500  
1505  
1510  
1515  
1520  
1525  
1530  
1535  
1540  
1545  
1550  
1555  
1560  
1565  
1570  
1575  
1580  
1585  
1590  
1595  
1600  
1605  
1610  
1615  
1620  
1625  
1630  
1635  
1640  
1645  
1650  
1655  
1660  
1665  
1670  
1675  
1680  
1685  
1690  
1695  
1700  
1705  
1710  
1715  
1720  
1725  
1730  
1735  
1740  
1745  
1750  
1755  
1760  
1765  
1770  
1775  
1780  
1785  
1790  
1795  
1800  
1805  
1810  
1815  
1820  
1825  
1830  
1835  
1840  
1845  
1850  
1855  
1860  
1865  
1870  
1875  
1880  
1885  
1890  
1895  
1900  
1905  
1910  
1915  
1920  
1925  
1930  
1935  
1940  
1945  
1950  
1955  
1960  
1965  
1970  
1975  
1980  
1985  
1990  
1995  
2000  
2005  
2010  
2015  
2020  
2025  
2030  
2035  
2040  
2045  
2050  
2055  
2060  
2065  
2070  
2075  
2080  
2085  
2090  
2095  
2100  
2105  
2110  
2115  
2120  
2125  
2130  
2135  
2140  
2145  
2150  
2155  
2160  
2165  
2170  
2175  
2180  
2185  
2190  
2195  
2200  
2205  
2210  
2215  
2220  
2225  
2230  
2235  
2240  
2245  
2250  
2255  
2260  
2265  
2270  
2275  
2280  
2285  
2290  
2295  
2300  
2305  
2310  
2315  
2320  
2325  
2330  
2335  
2340  
2345  
2350  
2355  
2360  
2365  
2370  
2375  
2380  
2385  
2390  
2395  
2400  
2405  
2410  
2415  
2420  
2425  
2430  
2435  
2440  
2445  
2450  
2455  
2460  
2465  
2470  
2475  
2480  
2485  
2490  
2495  
2500  
2505  
2510  
2515  
2520  
2525  
2530  
2535  
2540  
2545  
2550  
2555  
2560  
2565  
2570  
2575  
2580  
2585  
2590  
2595  
2600  
2605  
2610  
2615  
2620  
2625  
2630  
2635  
2640  
2645  
2650  
2655  
2660  
2665  
2670  
2675  
2680  
2685  
2690  
2695  
2700  
2705  
2710  
2715  
2720  
2725  
2730  
2735  
2740  
2745  
2750  
2755  
2760  
2765  
2770  
2775  
2780  
2785  
2790  
2795  
2800  
2805  
2810  
2815  
2820  
2825  
2830  
2835  
2840  
2845  
2850  
2855  
2860  
2865  
2870  
2875  
2880  
2885  
2890  
2895  
2900  
2905  
2910  
2915  
2920  
2925  
2930  
2935  
2940  
2945  
2950  
2955  
2960  
2965  
2970  
2975  
2980  
2985  
2990  
2995  
3000  
3005  
3010  
3015  
3020  
3025  
3030  
3035  
3040  
3045  
3050  
3055  
3060  
3065  
3070  
3075  
3080  
3085  
3090  
3095  
3100  
3105  
3110  
3115  
3120  
3125  
3130  
3135  
3140  
3145  
3150  
3155  
3160  
3165  
3170  
3175  
3180  
3185  
3190  
3195  
3200  
3205  
3210  
3215  
3220  
3225  
3230  
3235  
3240  
3245  
3250  
3255  
3260  
3265  
3270  
3275  
3280  
3285  
3290  
3295  
3300  
3305  
3310  
3315  
3320  
3325  
3330  
3335  
3340  
3345  
3350  
3355  
3360  
3365  
3370  
3375  
3380  
3385  
3390  
3395  
3400  
3405  
3410  
3415  
3420  
3425  
3430  
3435  
3440  
3445  
3450  
3455  
3460  
3465  
3470  
3475  
3480  
3485  
3490  
3495  
3500  
3505  
3510  
3515  
3520  
3525  
3530  
3535  
3540  
3545  
3550  
3555  
3560  
3565  
3570  
3575  
3580  
3585  
3590  
3595  
3600  
3605  
3610  
3615  
3620  
3625  
3630  
3635  
3640  
3645  
3650  
3655  
3660  
3665  
3670  
3675  
3680  
3685  
3690  
3695  
3700  
3705  
3710  
3715  
3720  
3725  
3730  
3735  
3740  
3745  
3750  
3755  
3760  
3765  
3770  
3775  
3780  
3785  
3790  
3795  
3800  
3805  
3810  
3815  
3820  
3825  
3830  
3835  
3840  
3845  
3850  
3855  
3860  
3865  
3870  
3875  
3880  
3885  
3890  
3895  
3900  
3905  
3910  
3915  
3920  
3925  
3930  
3935  
3940  
3945  
3950  
3955  
3960  
3965  
3970  
3975  
3980  
3985  
3990  
3995  
4000  
4005  
4010  
4015  
4020  
4025  
4030  
4035  
4040  
4045  
4050  
4055  
4060  
4065  
4070  
4075  
4080  
4085  
4090  
4095  
4100  
4105  
4110  
4115  
4120  
4125  
4130  
4135  
4140  
4145  
4150  
4155  
4160  
4165  
4170  
4175  
4180  
4185  
4190  
4195  
4200  
4205  
4210  
4215  
4220  
4225  
4230  
4235  
4240  
4245  
4250  
4255  
4260  
4265  
4270  
4275  
4280  
4285  
4290  
4295  
4300  
4305  
4310  
4315  
4320  
4325  
4330  
4335  
4340  
4345  
4350  
4355  
4360  
4365  
4370  
4375  
4380  
4385  
4390  
4395  
4400  
4405  
4410  
4415  
4420  
4425  
4430  
4435  
4440  
4445  
4450  
4455  
4460  
4465  
4470  
4475  
4480  
4485  
4490  
4495  
4500  
4505  
4510  
4515  
4520  
4525  
4530  
4535  
4540  
4545  
4550  
4555  
4560  
4565  
4570  
4575  
4580  
4585  
4590  
4595  
4600  
4605  
4610  
4615  
4620  
4625  
4630  
4635  
4640  
4645  
4650  
4655  
4660  
4665  
4670  
4675  
4680  
4685  
4690  
4695  
4700  
4705  
4710  
4715  
4720  
4725  
4730  
4735  
4740  
4745  
4750  
4755  
4760  
4765  
4770  
4775  
4780  
4785  
4790  
4795  
4800  
4805  
4810  
4815  
4820  
4825  
4830  
4835  
4840  
4845  
4850  
4855  
4860  
4865  
4870  
4875  
4880  
4885  
4890  
4895  
4900  
4905  
4910  
4915  
4920  
4925  
4930  
4935  
4940  
4945  
4950  
4955  
4960  
4965  
4970  
4975  
4980  
4985  
4990  
4995  
5000  
5005  
5010  
5015  
5020  
5025  
5030  
5035  
5040  
5045  
5050  
5055  
5060  
5065  
5070  
5075  
5080  
5085  
5090  
5095  
5100  
5105  
5110  
5115  
5120  
5125  
5130  
5135  
5140  
5145  
5150  
5155  
5160  
5165  
5170  
5175  
5180  
5185  
5190  
5195  
5200  
5205  
5210  
5215  
5220  
5225  
5230  
5235  
5240  
5245  
5250  
5255  
5260  
5265  
5270  
5275  
5280  
5285  
5290  
5295  
5300  
5305  
5310  
5315  
5320  
5325  
5330  
5335  
5340  
5345  
5350  
5355  
5360  
5365  
5370  
5375  
5380  
5385  
5390  
5395  
5400  
5405  
5410  
5415  
5420  
5425  
5430  
5435  
5440  
5445  
5450  
5455  
5460  
5465  
5470  
5475  
5480  
5485  
5490  
5495  
5500  
5505  
5510  
5515  
5520  
5525  
5530  
5535  
5540  
5545  
5550  
5555  
5560  
5565  
5570  
5575  
5580  
5585  
5590  
5595  
5600  
5605  
5610  
5615  
5620  
5625  
5630  
5635  
5640  
5645  
5650  
5655  
5660  
5665  
5670  
5675  
5680  
5685  
5690  
5695  
5700  
5705  
5710  
5715  
5720  
5725  
5730  
5735  
5740  
5745  
5750  
5755  
5760  
5765  
5770  
5775  
5780  
5785  
5790  
5795  
5800  
5805  
5810  
5815  
5820  
5825  
5830  
5835  
5840  
5845  
5850  
5855  
5860  
5865  
5870  
5875  
5880  
5885  
5890  
5895  
5900  
5905  
5910  
5915  
5920  
5925  
5930  
5935  
5940  
5945  
5950  
5955  
5960  
5965  
5970  
5975  
5980  
5985  
5990  
5995  
6000  
6005  
6010  
6015  
6020  
6025  
6030  
6035  
6040  
6045  
6050  
6055  
6060  
6065  
6070  
6075  
6080  
6085  
6090  
6095  
6100  
6105  
6110  
6115  
6120  
6125  
6130  
6135  
6140  
6145  
6150  
6155  
6160  
6165  
6170  
6175  
6180  
6185  
6190  
6195  
6200  
6205  
6210  
6215  
6220  
6225  
6230  
6235  
6240  
6245  
6250  
6255  
6260  
6265  
6270  
6275  
6280  
6285  
6290  
6295  
6300  
6305  
6310  
6315  
6320  
6325  
6330  
6335  
6340  
6345  
6350  
6355  
6360  
6365  
6370  
6375  
6380  
6385  
6390  
6395  
6400  
6405  
6410  
6415  
6420  
6425  
6430  
6435  
6440  
6445  
6450  
6455  
6460  
6465  
6470  
6475  
6480  
6485  
6490  
6495  
6500  
6505  
6510  
6515  
6520  
6525  
6530  
6535  
6540  
6545  
6550  
6555  
6560  
6565  
6570  
6575  
6580  
6585  
6590  
6595  
6600  
6605  
6610  
6615  
6620  
6625  
6630  
6635  
6640  
6645  
6650  
6655  
6660  
6665  
6670  
6675  
6680  
6685  
6690  
6695  
6700  
6705  
6710  
6715  
6720  
6725  
6730  
6735  
6740  
6745  
6750  
6755  
6760  
6765  
6770  
6775  
6780  
6785  
6790  
6795  
6800  
6805  
6810  
6815  
6820  
6825  
6830  
6835  
6840  
6845  
6850  
6855  
6860  
6865  
6870  
6875  
6880  
6885  
6890  
6895  
6900  
6905  
6910  
6915  
6920  
6925  
6930  
6935  
6940  
6945  
6950  
6955  
6960  
6965  
6970  
6975  
6980  
6985  
6990  
6995  
7000  
7005  
7010  
7015  
7020  
7025  
7030  
7035  
7040  
7045  
7050  
7055  
7060  
7065  
7070  
7075  
7080  
7085  
7090  
7095  
7100  
7105  
7110  
7115  
7120  
7125  
7130  
7135  
7140  
7145  
7150  
7155  
7160  
7165  
7170  
7175  
7180  
7185  
7190  
7195  
7200  
7205  
7210  
7215  
7220  
7225  
7230  
7235  
7240  
7245  
7250  
7255  
7260  
7265  
7270  
7275  
7280  
7285  
7290  
7295  
7300  
7305  
7310  
7315  
7320  
7325  
7330  
7335  
7340  
7345  
7350  
7355  
7360  
7365  
7370  
7375  
7380  
7385  
7390  
7395  
7400  
7405  
7410  
7415  
7420  
7425  
7430  
7435  
7440  
7445  
7450  
7455  
7460  
7465  
7470  
7475  
7480  
7485  
7490  
7495  
7500  
7505  
7510  
7515  
7520  
7525  
7530  
7535  
7540  
7545  
7550  
7555  
7560  
7565  
7570  
7575  
7580  
7585  
7590  
7595  
7600  
7605  
7610  
7615  
7620  
7625  
7630  
7635  
7640  
7645  
7650  
7655  
7660  
7665  
7670  
7675  
7680  
7685  
7690  
7695  
7700  
7705  
7710  
7715  
7720  
7725  
7730  
7735  
7740  
7745  
7750  
7755  
7760  
7765  
7770  
7775  
7780  
7785  
7790  
7795  
7800  
7805  
7810  
7815  
7820  
7825  
7830  
7835  
7840  
7845  
7850  
7855  
7860  
7865  
7870  
7875  
7880  
7885  
7890  
7895  
7900  
7905  
7910  
7915  
7920  
7925  
7930  
7935  
7940  
7945  
7950  
7955  
7960  
7965  
7970  
7975  
7980  
7985  
7990  
7995  
8000  
8005  
8010  
8015  
8020  
8025  
8030  
8035  
8040  
8045  
8050  
8055  
8060  
8065  
8070  
8075  
8080  
8085  
8090  
8095  
8100  
8105  
8110  
8115  
8120  
8125  
8130  
8135  
8140  
8145  
8150  
8155  
8160  
8165  
8170  
8175  
8180  
8185  
8190  
8195  
8200  
8205  
8210  
8215  
8220  
8225  
8230  
8235  
8240  
8245  
8250  
8255  
8260  
8265  
8270  
8275  
8280  
8285  
8290  
8295  
8300  
8305  
8310  
8315  
8320  
8325  
8330  
8335  
8340  
8345  
8350  
8355  
8360  
8365  
8370  
8375  
8380  
8385  
8390  
8395  
8400  
8405  
8410  
8415  
8420  
8425  
8430  
8435  
8440  
8445  
8450  
8455  
8460  
8465  
8470  
8475  
8480  
8485  
8490  
8495  
8500  
8505  
8510  
8515  
8520  
8525  
8530  
8535  
8540  
8545  
8550  
8555  
8560  
8565  
8570  
8575  
8580  
8585  
8590  
8595  
8600  
8605  
8610  
8615  
8620  
8625  
8630  
8635  
8640  
8645  
8650  
8655  
8660  
8665  
8670  
8675  
8680  
8685  
8690  
8695  
8700  
8705  
8710  
8715  
8720  
8725  
8730  
8735  
8740  
8745  
8750  
8755  
8760  
8765  
8770  
8775  
8780  
8785  
8790  
8795  
8800  
8805  
8810  
8815  
8820  
8825  
8830  
8835  
8840  
8845  
8850  
8855  
8860  
8865  
8870  
8875  
8880  
8885  
8890  
8895  
8900  
8905  
8910  
8915  
8920  
8925  
8930  
8935  
8940  
8945  
8950  
8955  
8960  
8965  
8970  
8975  
8980  
8985  
8990  
8995  
9000  
9005  
9010  
9015  
9020  
9025  
9030  
9035  
9040  
9045  
9050  
9055  
9060  
9065  
9070  
9075  
9080  
9085  
9090  
9095  
9100  
9105  
9110  
9115  
9120  
9125  
9130  
9135  
9140  
9145  
9150  
9155  
9160  
9165  
9170  
9175  
9180  
9185  
9190  
9195  
9200  
9205  
9210  
9215  
9220  
9225  
9230  
9235  
9240  
9245  
9250  
9255  
9260  
9265  
9270  
9275  
9280  
9285  
9290  
9295  
9300  
9305  
9310  
9315  
9320  
9325  
9330  
9335  
9340  
9345  
9350  
9355  
9360  
9365  
9370  
9375  
9380  
9385  
9390  
9395  
9400  
9405  
9410  
9415  
9420  
9425  
9430  
9435  
9440  
9445  
9450  
9455  
9460  
9465  
9470  
9475  
9480  
9485  
9490  
9495  
9500  
9505  
9510  
9515  
9520  
9525  
9530  
9535  
9540  
9545  
9550  
9555  
9560  
9565  
9570  
9575  
9580  
9585  
9590  
9595  
9

Figure 4 - Effects of AX-15 in *ob/ob* mice. C57BL/6J *ob/ob* mice were injected subcutaneously daily for 7 days with either vehicle, leptin (1.0 mg/kg) or AX-15 at 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg or 3.0 mg/kg. Diet-restricted, pair-fed (PF) mice were injected with 0.3 mg/kg AX-15 to investigate the effects of food intake reduction on weight loss. Percent change in body weight in AX-15-treated and leptin-treated versus vehicle-treated controls is shown.

Figure 5 - Effects of AX-15 in diet-induced obesity in mice. AKR/J mice were placed on a high fat diet for seven weeks prior to treatment with vehicle, leptin (1.0 mg/kg) or AX-15 at 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, or 1.0 mg/kg. Diet-restricted, pair-fed AKR/J mice were injected with 0.1 mg/kg AX-15 (PF-AX-15) to investigate the effects of food intake reduction on weight loss. Percent change in body weight in AX-15 - treated and leptin-treated versus vehicle-treated controls is shown.

Figures 6A and 6B - Effects of AX-15 and diet restriction on serum insulin and corticosterone levels in diet-induced obese AKR/J mice. Figure 6A- Serum insulin levels were measured in AKR/J diet-induced obese mice following treatment with vehicle, diet restriction and AX-15 (0.1 mg/kg) (PF-AX-15) or AX-15 only (0.1 mg/kg) to determine the effects of diet and/or AX-15 treatment on obesity-associated hyperinsulinemia. Figure 6B- Serum corticosterone levels were measured in AKR/J diet induced obese mice following treatment with vehicle, diet restriction and AX-15 (0.1 mg/kg) (PF-AX-15) or AX-15 only (0.1 mg/kg).

Figure 7 - Effect of intranasal delivery of AX-15 on body weight reduction in diet-induced obese AKR/J mice. DIO mice were given daily intranasal administration of either vehicle (□) or AX-15 (94  $\mu$ g/mouse in 50  $\mu$ l, approximately 1.87-2.35 mg/kg) (○) for 7 days. A group of mice receiving daily subcutaneous injection of AX-15 (O) at 0.1 mg/kg was also included for comparison. The animals were weighed daily and

mean body weight change was expressed as percent change from baseline +/- SEM (n= 5 or 10 per group).

Figure 8 - Effect of intranasal delivery of AX-15 on food intake in diet-induced obese 5 AKR/J mice. DIO mice were given daily intranasal administration of either vehicle (□) or AX-15 (94 µg/mouse in 50 µl, approximately 1.87-2.35 mg/kg) (◊) for 7 days. A group of mice receiving daily subcutaneous injection of AX-15 (○) at 0.1 mg/kg was also included for comparison. Food consumed by individual animals was determined daily and expressed as mean +/- SEM (n= 5 or 10 per group).

10

Figure 9 - Pharmacokinetic profile of AX-15 administered via intranasal route.

Pharmacokinetics of AX-15 delivered by intranasal administration was determined in female BALB/c mice (100 µg/mouse in 50 µl, equivalent to 3.3 mg/kg; n=3). Sera were obtained from tail bleeds at 0, 0.5, 1, 2, 4, 8, and 24 hour intervals after administration. Levels of AX-15 were measured by a 2-site ELISA, using a monoclonal antibody to CNTF as capture.

#### DETAILED DESCRIPTION OF THE INVENTION

20 The present invention relates to a method of administering a CNTF protein to treat diseases and disorders in humans or animals.

Recombinant human and rat CNTF have the same number of amino acids (199) and similar mass (MW 22,798 and 22,721 respectively, after removal of the N-terminal 25 methionine). Yet, on reducing SDS PAGE gels, recombinant human CNTF migrates as a protein of MW=27,500, whereas rat CNTF migrates with the expected mobility. In addition, human CNTF has four times lower biological activity towards chick ciliary ganglion (CG) neurons than rat CNTF and the human protein competes for binding to the human or the rat receptor on cell surfaces much less effectively than 30 rat CNTF.

*Sub B2*

The above observations led to a directed effort to identify the region on the CNTF molecule responsible for these differences. This method involved the exchange, by genetic engineering methods, of parts of the human CNTF sequence with the 5 corresponding rat CNTF sequence and vice versa. To achieve this, advantage was taken of restriction sites that are common to the two CNTF genes and unique in their corresponding expression vectors. When necessary, such sites were engineered in one or the other of the two genes in areas that encode the same protein sequence. With this approach, expression vectors were obtained for each of 10 the modified proteins shown in Figure 1. After expressing and isolating the individual proteins to at least 60% purity, their properties, as compared to those of human and rat CNTF, were determined.

Because the electrophoretic mobilities of human and rat CNTF differ significantly, the effect of each amino acid substitution was monitored initially by making a determination of the effect of such change on the mobility of the protein. As described herein, electrophoretic mobility data indicated that all of the modified human CNTF molecules that migrated to the same position as rat CNTF had the single amino acid substitution Gln63Arg (Q63R), in which glutamine at position 63 is replaced with arginine.

CNTF is characterized by its capacity to support the survival of dissociated ciliary neurons of E8 chick embryos. By this criterion, purified recombinant rat CNTF is as active as the native protein from rat, but four times more active than recombinant 25 human CNTF (Masiakowski, et al., 1991, *J. Neurosci.* 57:1003-1012 and in International Publication No. WO 91/04316, published on April 4, 1991). The same assay was utilized to determine the biological activity of the altered molecules prepared as described above. As described herein, all modified CNTF molecules that had the Q63R substitution exhibited an increased ability to support the survival of 30 ciliary ganglion neurons as compared to the parent human CNTF protein. Such results indicated a strong correlation between alteration electrophoretic mobility and

enhanced biological properties. In addition to measuring the biological effect of modifications made to human CNTF, an indication of the potential biological activity of each of the molecules may also be obtained by determining the effect of each modification on the ability of the molecules to bind to the CNTF receptor.

5

As used herein, the terms "a ciliary neurotrophic factor protein", "a CNTF protein", "a ciliary neurotrophic factor molecule" and "a CNTF molecule" refer to human ciliary neurotrophic factor and modified ciliary neurotrophic factors.

10 As used herein, the terms "modified ciliary neurotrophic factor", "modified CNTF", "modified ciliary neurotrophic factor protein" and "modified CNTF protein" refer to CNTF proteins and polypeptides that have certain amino acid substitutions and/or deletions in the amino acid residue sequence of human CNTF which result in modified CNTF proteins and polypeptides that exhibit binding to the CNTF receptor and, therefore, would be expected to have enhanced biological, immunogenic and/or purification properties. CNTF proteins of the present invention may also be "pegylated" by the addition of polyethylene glycol polymers in order to enhance stability and/or bioavailability. A particularly preferred "modified ciliary neurotrophic factor" according to the invention, contains certain amino acid substitutions and deletions in the human CNTF protein and exhibits enhanced binding to the human CNTF receptor and therefore, would be expected to have enhanced biological properties, and specifically include AX-13, AX-2 and AX-15, described in more detail *infra*.

25 The CNTF molecules useful for practicing the present invention may be prepared by cloning and expression in a prokaryotic or eukaryotic expression system as described, for example in Masiakowski, et al., 1991, *J. Neurosci.* 57:1003-1012 and in International Publication No. WO 91/04316, published on April 4, 1991. The recombinant CNTF gene may be expressed and purified utilizing any number of 30 methods. The gene encoding this protein may be subcloned into a bacterial expression vector, such as for example, but not by way of limitation, pCP110.

The recombinant CNTF proteins may be purified by any technique which allows for the subsequent formation of a stable, biologically active protein. For example, and not by way of limitation, they may be recovered from 5 cells either as soluble proteins or as inclusion bodies, from which they may be extracted quantitatively by 8M guanidinium hydrochloride and dialysis. Further purification of the proteins, may be done by conventional ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography or gel filtration.

10

According to the present invention, CNTF proteins produced as described herein, or hybrids or mutants thereof, may be used to promote differentiation, proliferation or survival in vitro or in vivo of cells that are responsive to CNTF, including cells that express receptors of the CNTF/IL-6/LIF receptor family, or any cells that express the appropriate signal transducing component, as described, for example, in Davis, et al., 1992, Cell 69:1121-1132. Mutants or hybrids may alternatively antagonize cell differentiation or survival.

The present invention may be used to treat disorders of any cell responsive to CNTF or the CNTF/CNTF receptor complex. In preferred embodiments of the invention, disorders of cells that express members of the CNTF/IL-6/LIF receptor family may be treated according to these methods. Examples of such disorders include, but are not limited to, obesity and diabetes.

25 Accordingly, the present invention provides for methods in which a patient is treated with an effective amount of the modified CNTF protein, or a hybrid or mutant thereof. The modified CNTF proteins may be utilized to treat disorders or diseases as described for CNTF in International Publication No. WO91/04316 published on April 4, 1991 by Masiakowski, et al. and for the CNTF/CNTFR complex 30 as described in International Publication No. WO91/19009 published on December

12, 1991 by Davis, et al. both of which are incorporated by reference in their entirety herein.

Such diseases or disorders include degenerative diseases, such as retinal  
5 degenerations, diseases or disorders involving the spinal cord, cholinergic neurons, hippocampal neurons or diseases or disorders involving motor neurons, such as amyotrophic lateral sclerosis or those of the facial nerve, such as Bell's palsy. Other diseases or disorders that may be treated include obesity and diabetes

10 Human clinical trials using recombinant human CNTF (rHCNTF) have been carried out wherein subcutaneous administration of the protein was tested for its efficacy in slowing the progression of amyotrophic lateral sclerosis (ALS). Such administration of rHCNTF was associated with systemic side effects, including cough, anorexia and weight loss, and, in at least one study, over 80% of patients receiving rHCNTF developed neutralizing antibodies, the significance of which is uncertain. However, despite problems with side effects and antibody formation, a subgroup of patients in the early stages of ALS appeared to derive benefit from rHCNTF administration in that these patients demonstrated a reduced rate of pulmonary function loss compared to placebo treated patients with similar disease durations. It was also found, in a clinical trial testing the use of CNTF for treating ALS, that administration of CNTF to humans reduced food intake which resulted in weight loss (Group, A. C. T. S. (1996) Neurology 46:1244-1249.).

20

25 Applicants have previously reported that rHCNTF lacking the last 13 amino acid residues from the carboxyl end (rHCNTF $\Delta$ C13 also designated RPN160 or RG160) retains full biological activity and is soluble at low temperatures (5-10°C) to at least 12 mg/ml. Yet, despite this far greater solubility, rHCNTF $\Delta$ C13 precipitates in a PBS solution upon incubation at 37°C for several hours, even at concentrations as low as 0.1 mg/ml.

It was determined that the thermal instability of rHCNTF and rHCNTF $\Delta$ C13 was the result of aggregation that was initiated by intermolecular disulfide bond formation and depended strongly on protein concentration and temperature. By replacing the single cysteine residue at position 17 of human CNTF with an alanine residue,

5 modified CNTF proteins were obtained that exhibited far greater stability and maintained their biological activity after incubation for at least 7 days in PBS at 37°C. This property is maintained in rHCNTF, Q63R variants which have higher potency due to the substitution of the glutamine residue at position 63 by arginine. In a particular example, rHCNTF, C17A, Q63R,  $\Delta$ C13 (also designated RG297) shows  
10 greater biological potency than rHCNTF because of the Q63R substitution, greater solubility because of the  $\Delta$ C13 deletion and greater stability because of the C17A substitution.

Applicants have also previously described the production of this modified CNTF molecule, known alternatively as AX-13 or AX-1, (designated rHCNTF, C17A, Q63R $\Delta$ C13) which combines a Q63R substitution (which confers greater biological potency) with a deletion of the C-terminal 13 amino acid residues (which confers greater solubility under physiological conditions) and a C17A substitution (which confers stability, particularly under physiological conditions at 37°C) and shows a 2-3 fold better therapeutic index than rHCNTF in an animal model. However, when expressed in E. coli, a substantial portion of the expressed protein produced is tagged with a decapeptide at the C-terminus. Because of this, purification of AX-13 is difficult and results in a low yield of purified, untagged product. This decapeptide tagging likely does not occur when the AX-13 is expressed in a mammalian  
25 expression system. In addition, it is possible that the decapeptide tag could contribute to increased immunogenicity of the molecule and may also possibly cause problems with stability. However, because the use of the E. coli expression system would be preferable from the standpoint of cost and efficiency, applicants undertook to develop a further truncated CNTF molecule that would retain the  
30 improved potency, solubility and stability properties of AX-13, while avoiding the

15  
20  
25  
30

problem of decapeptide tagging when expressed in E. coli. As described herein, applicants have succeeded in producing such a molecule designated AX-15, (rHCNTF, C17A, Q63R $\Delta$ C15), which retains the improved properties of AX-13, and has an additional C-terminal truncation of two amino acids, but which also has the 5 added advantage of being expressed by E. coli with reduced amino acid tag being added. The new molecule, AX-15, therefore has the advantage of being more easily purified with a greater yield. Another embodiment of a modified CNTF in the present invention is AX-2, which has a C17A substitution in the amino acid residue sequence of human CNTF and a truncation of the 15 C-terminal amino acid 10 residues of human CNTF. AX-2, (rHCNTF, C17A  $\Delta$ C15), differs from AX-15 solely in the absence of the Q63R substitution that is present in AX-15.

The present invention contemplates a composition comprising a ciliary neurotrophic factor protein of the invention, such as the protein described herein as AX-15, and a carrier.

Another object of the present invention is to provide a method of treating a disease or disorder comprising administering CNTF or a modified ciliary neurotrophic factor, such as the protein described herein as AX-15. The disease or disorder treated may be a degenerative disease and/or involve the spinal cord, motor neurons, cholinergic neurons or cells of the hippocampus. Alternatively, the method of treatment may be for treating a disease or disorder such as obesity or diabetes or treating a disease or disorder involving muscle atrophy.

25 A further object of the present invention is to provide a method of inducing weight loss in a mammal comprising administration to the mammal of a ciliary neurotrophic factor protein, particularly AX-15. A specific embodiment of this invention involves inducing weight loss in a human.

The method of administering a CNTF protein, such as AX-15, may be used in the treatment of diet induced obesity or obesity of a genetically determined origin. In a preferred embodiment, a modified CNTF protein, such as AX-15 described herein, may also be used in a method of preventing and/or treating the occurrence of  
5 gestational or adult onset diabetes in a human.

Any of the above-described methods involving the administration of CNTF or a modified CNTF, such as AX-15 described herein, may be practiced by administering the CNTF protein via a route of delivery selected from the group consisting of  
10 intravenous, intramuscular, intraocular, subcutaneous, intranasal, respiratory or intratracheal, such as by use of a nebulizer, and by intracolonic or vaginal suppositories. Alternatively, a CNTF protein, such as AX-15 described herein, may be administered via the implantation of cells that release the modified ciliary neurotrophic factor.

The present invention also provides for pharmaceutical compositions comprising CNTF or a modified CNTF protein or hybrid or mutant thereof, such as AX-15 described herein, as the sole therapeutic agent or in a complex with the CNTF receptor, in a suitable pharmacologic carrier for use in the treatment of obesity or gestational or adult onset diabetes.

The active ingredient, which may comprise CNTF or a modified CNTF should be formulated in a suitable pharmaceutical carrier for administration in vivo by any appropriate route including, but not limited to intranasal, intratracheal, by  
25 nebulizer, intraocular and oral.

As used herein, "intranasal administration" refers to delivery to the nose or nasal passageways by spray, drops, gel, inhalant or other means.

30 As used herein, "intratracheal administration" refers to delivery to the throat or tracheal lumen by spray, propellant, atomizer, injection or other means.

As used herein, "by nebulizer" refers to the use of any device which reduces the formulation of the present invention to a fine spray for penetration into the lungs or nasal cavities.

5 As used herein, "intraocular administration" refers to delivery to the eye by drop, spray, ointment or other means.

As used herein, "oral administration" refers to delivery to the mouth, esophagus or stomach by pill, capsule, solution, tablet, lozenge, powder, spray or other means.

10

Depending upon the mode of administration, the active ingredient may be formulated in a liquid carrier such as saline, incorporated into liposomes, microcapsules, polymer or wax-based and controlled release preparations. In preferred embodiments, modified CNTF preparations are stable solutions, or formulated into tablet, pill or capsule forms.

15  
20  
25

The concentration of the active ingredient used in the formulation will depend upon the effective dose required and the mode of administration used. The dose used should be sufficient to achieve circulating plasma concentrations of active ingredient that are efficacious. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems. Effective doses are expected to be within the range of from about .001 to about 1 mg/day.

### EXAMPLES

25

#### Example 1 - Electrophoretic Mobility of Modified Human CNTF Molecules

##### Materials and Methods

##### Preparation of Modified CNTF molecules

##### Bacterial Strains and Plasmids

30 E. coli K-12 RFJ26 is a strain that overproduces the lactose operon repressor.

The expression vectors pRPN33, which carries the human CNTF gene and pRPN110 which carries the rat CNTF gene are nearly identical (Masiakowski, et al., 1991, J. Neurosci. 57:1003-1012 and in International Publication No. WO 91/04316, published on April 4, 1991.)

5

Plasmid pRPN219 was constructed by first digesting pRPN33 with the restriction enzymes Nhe1 plus Hind3 and gel purifying the 4,081 bp fragment. The second, much smaller fragment which codes for part of the human CNTF gene was subsequently replaced with an 167 bp Nhe1-Hind3 fragment that was obtained by PCR amplification from the rat gene using the primers RAT-III-dniH: 5' ACGGTAAGCT TGGAGGTTCTC 3' and RAT-Nhe-I-M: 5' TCTATCTGGC TAGCAAGGAA GATTCGTTCA GACCTGACTG CTCTTACG 3'.

10

Plasmid pRPN228 was constructed in the same manner as pRPN219, except that the 167 bp replacement fragment was amplified using the DNA primers Rat-III-dniH-L-R : 5' AAG GTA CGA TAA GCT TGG AGG TTC TCT TGG AGT CGC TCT GCC TCA GTC AGC TCA CTC CAA CGA TCA GTG 3' and Rat-Nhe-I: 5' TCT ATC TGG CTA GCA AGG AAG 3'.

15

Plasmids pRPN186, pRPN187, pRPN188, pRPN189, pRPN192, pRPN218, and pRPN222 were generated by similar means or by direct exchange of DNA fragments using the unique restriction sites shown in Figure 1.

20

Sub B3

25

The identity of all plasmids was confirmed by restriction analysis and DNA sequencing.

### Protein Purification

30

Induction of protein synthesis, selective extraction, solubilization and purification from inclusion bodies were as described for rat and human CNTF (Masiakowski, et al., 1991, J. Neurosci. 57:1003-1012 and in International Publication No. WO

91/04316, published on April 4, 1991) except that gel filtration was occasionally used instead or in addition to ion exchange chromatography. Alternatively, proteins were purified from the supernatants of cell lysates by streptomycin and ammonium sulfate fractionation, followed by column chromatography, as described for other 5 proteins (Panayotatos et al., 1989, *J. Biol. Chem.* **264**:15066-15069). All proteins were isolated to at least 60% purity.

Conditions for enzymatic reactions, DNA electrophoresis and other techniques used in these studies have been described in detail (Panayotatos, N. 1987, *Engineering an 10 Efficient Expression System in Plasmids: A practical Approach* (Hardy, K.G. ed.) pp 163-176, IRL Press, Oxford, U.K.).

0  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
00

### Results

The mobilities of human, rat and several chimeric CNTF molecules on reducing SDS-polyacrylamide gels are shown in Figure 2. The chimeric molecules RPN186, RPN189, RPN218 and RPN228 exhibit mobilities comparable to rat CNTF, whereas RPN187, RPN188, RPN192 and RPN222 exhibit mobilities comparable to human CNTF. Cross reference of these results to the aligned sequences of these proteins in Figure 1 reveals that all proteins carrying an arginine residue at position 63 (R63) display the mobility of rat CNTF. In the case of RPN228, a single amino acid substitution (Q63→R) is sufficient to confer to human CNTF the normal mobility of rat CNTF.

25

Figure 2 also provides a measure of the purity of the different recombinant proteins. By visual inspection, purity varies from 60% for RPN189 to better than 90% for RPN228.

## Example 2 - Measurement of Binding Activity of Modified CNTF Molecules

### Materials and Methods

#### Preparation of $^{125}\text{I}$ -CNTF

5 Recombinant rat CNTF (28 mg) in 37 ml 0.2 M sodium borate buffer, pH 8.5 was transferred to a vial containing 4 mCi, (2,000 Ci/mmole; NEN) of  $^{125}\text{I}$  and reagent (Bolton and Hunter, 1973, Biochem J. 133: 529-539) which had been dried under a gentle stream of nitrogen. Reactions were incubated for 45 min at 0°C followed by 15 min at room temperature and terminated by the addition of 30 ml of 0.2 M glycine solution. After 15 min, 0.2 ml PBS containing 0.08 % gelatin was also added and the mixture was passed through a Superdex-75™ column (Pharmacia) to separate the labeled monomeric CNTF from dimeric and other multimeric derivatives. Percentage of incorporation was typically 20%, as determined by thin layer chromatography and the specific activity was typically around 1,000 Ci/mmole. The monomeric  $^{125}\text{I}$ -CNTF was stored at 4°C and used up to one week after preparation. As a test of structural and conformational integrity,  $^{125}\text{I}$ -CNTF (approximately 10,000 cpm) was mixed with a 5 mg unlabelled CNTF and analyzed by native gel electrophoresis. One major band was visible by either Coomassie staining or autoradiography.  $^{125}\text{I}$ -CNTF also showed comparable activity to native CNTF in supporting survival of E8 chick ciliary neurons in culture.

#### Tissue Culture Techniques

Superior cervical ganglia (SCG) from neonatal rats were treated with trypsin (0.1%), mechanically dissociated and plated on a poly ornithine (30 mg/ml) substratum. 25 Growth medium consisted of Ham's nutrient mixture F12 with 10% heat-inactivated fetal bovine serum (Hyclone), nerve growth factor (NGF) (100 ng/ml), penicillin (50 U/ml) and streptomycin (50 mg/ml). Cultures were maintained at 37°C in a humidified 95% air/5% CO<sub>2</sub> atmosphere. Ganglion non-neuronal cells were eliminated by treatment with araC (10 mM) on days 1 and 3 of culture.

Cultures were fed 3 times/week and were routinely used for binding assays within 2 weeks.

5 MG87/CNTFR is a fibroblast cell line transfected with the human CNTF $\alpha$  receptor gene (Squinto, et al., 1990, Neuron 5:757-766; Davis et al., 1991, Science 253:59-63).

### Binding Assays

10 Binding was performed directly on cell monolayers. Cells in culture wells were washed once with assay buffer consisting of phosphate buffered saline (PBS; pH 7.4), 0.1 mM bacitracin, 1 mM PMSF, 1 mg/ml leupeptin, and 1 mg/ml BSA. After incubation with  $^{125}$ I-CNTF for 2 hours at room temperature, cells were quickly washed twice with assay buffer, lysed with PBS containing 1 % SDS and counted in a Packard Gamma Counter. Non-specific binding was determined in the presence of 1,000-fold excess of unlabelled CNTF. Specific binding towards MG87/CNTFR was 80-90%. Data were analyzed using the GRAPHPAD program (ISI, Philadelphia, PA).

### Results

20 Both rat and human CNTF compete with  $^{125}$ I-rat CNTF for binding to SCG neurons, but human CNTF ( $IC_{50} = 25$  nM) is 90 times less potent in displacing  $^{125}$ I-rat CNTF binding than unlabelled rat CNTF ( $IC_{50} = 0.28$  nM). In contrast, RPN219 is almost as potent as rat CNTF and clearly more potent than human CNTF ( $IC_{50} = 0.3$  nM).

25 Similar results were obtained from competition experiments with mouse fibroblasts transfected with a plasmid directing the expression of the human CNTF receptor. Both rat, human and RPN228 compete with  $^{125}$ I-rat CNTF for binding to MG87/CNTFR cells. Human CNTF ( $IC_{50} = 30$  nM) is 12 times less potent than rat CNTF ( $IC_{50} = 2.8$  nM), whereas RPN228 is clearly more potent than the human protein ( $IC_{50} = 5.6$  nM).

Competition binding experiments with the other modified CNTF proteins shown in Figure 1 also demonstrated that proteins having R63 displayed the biological activity of rat CNTF, whereas proteins having Q63 displayed the binding properties of human CNTF (data not shown). These results indicate that the single amino acid 5 substitution (Q63->R) is sufficient to confer to human CNTF the receptor binding properties characteristic of rat CNTF.

Example 3 - Construction of AX-15 Expression Plasmid pRG643

Sub. B6  
10 The expression plasmid pRG632 is a high copy plasmid that encodes ampicillin resistance and the gene for human CNTF-C17A,Q63R $\Delta$ C13 (also referred to herein as either AX-1 or AX-13) with a unique Eag I restriction enzyme recognition sequence 3' to the stop codon. This plasmid was used to construct a human CNTF mutation C17A,Q63R, $\Delta$ C15 (designated AX-15) by PCR amplification of a 187 bp BseR I-Eag1 DNA fragment that incorporates the  $\Delta$ C15 mutation. The 5' primer { $\Delta$ C15- 5' (5'-CCAGATAGAGGAGTTAATGATACTCCT-3')} encodes the BseR I site and the 3' primer , $\Delta$ C15-3' {(5'-GCCTGGCCGGACCACGCTCATTACCCAGTCT GTGAGAAGAAATG-3')} encodes the C-terminus of the AX-15 gene ending at Gly185 followed by two stop codons and an Eag I restriction enzyme recognition sequence. This DNA fragment was digested with BseR I and Eag I and ligated into the same sites in pRG632. The resulting plasmid, pRG639, encodes the gene for AX- 20 15 (human CNTF C17A,Q63R,  $\Delta$ C15). The  $\Delta$ C15 mutation was then transferred as a 339 bp Hind III-Eag I DNA fragment into the corresponding sites within pRG421, a high copy number expression plasmid encoding the gene for kanamycin resistance 25 and human CNTF C17A,Q63R, $\Delta$ C13. The resulting plasmid, pRG643, encodes the gene for AX-15 under transcriptional control of the lacUV5 promoter, and confers kanamycin resistance. The AX-15 gene DNA sequence was confirmed by sequence analysis.

#### EXAMPLE 4 - PEGylation of CNTF Proteins

Pegylation of proteins has been shown to increase their *in vivo* potency by enhancing stability and bioavailability while minimizing immunogenicity. It is

5 known that the properties of certain proteins can be modulated by attachment of polyethylene glycol (PEG) polymers, which increases the hydrodynamic volume of the protein and thereby slows its clearance by kidney filtration. (See, e.g. Clark, R., et al., 1996, *J. Biol. Chem.* 271: 21969-21977). We have generated PEGylated CNTF proteins by covalently linking polyethylene glycol (PEG) to AX-13. We have also  
10 developed a purification methodology to separate different PEGylated forms of CNTF proteins from non-pegylated molecules. PEGylated AX-13 has better solubility and stability properties, at physiological pH, than unPEGylated AX-13. PEGylation has been shown to greatly enhance pharmacokinetic properties of AX-13 and would be expected to similarly enhance the properties of other CNTF proteins.

20 Purified AX-13 derived from E. coli was used for these studies. 20kD mPEG-SPA was obtained from Shearwater Polymers, Bicine from Sigma, and Tris-Glycine precast gels from Novex, CA. A small scale reaction study was set up to determine reaction conditions. 20kD mPEG SPA was reacted with purified AX-13 at a final concentration of 0.6 mg/ml, at 4°C in an amine-free buffer at a pH of 8.1. Molar ratios of PEG to protein were varied and two reaction times were used. The reaction was stopped by the addition of a primary amine in large excess. Reaction products were analyzed by reducing SDS-PAGE. The predominant modified species ran at a molecular weight of approximately 60 kD. Higher order modified bands that ran at  
25 higher molecular weights were also seen. Based on this study, an overnight reaction at a PEG-to-protein ratio of 4 was chosen.

AX-13 at 0.6 mg/mL was reacted with 20 kD mPEG SPA in a Bicine buffer overnight at 4°C at a pH of 8.1. The reaction was stopped by the addition of a primary amine in  
30 large excess. The reaction product was diluted with a low salt buffer and applied to an ion-exchange column. The column was washed with a low salt buffer and eluted

with a NaCl gradient. A good separation between higher order forms (apparent MW >66kD on SDS-PAGE), a distinct pegylated species that ran at about 60kD and unpegylated AX-13 was obtained. Fractions corresponding to the 60kD band were tested in a bioassay. A very faint band of unpegylated AX-13 was noticed in the 5 fractions corresponding to the 60kD band. To ensure that the bioassay results were not influenced significantly by this material, the 60kD band was further purified by size exclusion chromatography (SEC) that resulted in baseline separation between unpegylated AX-13 and the 60kD band. The purified pegylated AX-13 was tested in a bioassay and the results were indistinguishable from those obtained with the 10 material prior to SEC.

## EXAMPLE 5 - Small Scale Expression and Purification of AX-15 protein

*E. coli* strain RFJ141 containing pRG639 was grown in LB medium and expression of AX-15 protein was induced by the addition of lactose to 1% (w/v). Induced cells were harvested by centrifugation, resuspended in 20 mM Tris-HCl, pH 8.3, 5 mM EDTA, 1 mM DTT, and lysed by passage through a French pressure cell at 10,000 psi. The cell lysate was centrifuged and the pellet was resuspended in 8 M guanidinium-HCl, 50 mM Tris-HCl, pH 8.3, 0.05 mM EDTA then diluted with 5 volumes of 50 mM Tris-HCl, pH 8.3, 0.05 mM EDTA (Buffer A) followed by dialysis against Buffer A. The dialysate was loaded onto a Q-sepharose column equilibrated with Buffer A. The AX-15 protein was eluted by a linear gradient to 1 M NaCl in 10 column volumes of buffer. Fractions containing AX-15 were pooled and brought to 1 M  $(\text{NH}_4)_2\text{SO}_4$  by the slow addition of solid  $(\text{NH}_4)_2\text{SO}_4$  while maintaining the pH at 8.3 by the addition of NaOH. The pool was loaded onto a phenyl-sepharose column equilibrated with 1 M  $(\text{NH}_4)_2\text{SO}_4$  in Buffer A. The column was washed with 0.5 M  $(\text{NH}_4)_2\text{SO}_4$  in Buffer A, and the AX-15 protein was eluted by a linear gradient of decreasing  $(\text{NH}_4)_2\text{SO}_4$  concentration. Fractions containing AX-15 protein were pooled, dialyzed against 5 mM NaPO<sub>4</sub>, pH 8.3, then concentrated by ultrafiltration. The concentrated pool was fractionated on a Sephadryl S-100 column equilibrated with 5 mM NaPO<sub>4</sub>, pH 8.3.

**EXAMPLE 6 - Large Scale Expression and Purification of AX-15 protein**

A recombinant, kanamycin resistant *E. coli* strain RFJ141 expressing the AX-15 protein under lac promoter control (pRG643) was grown to an intermediate density of 30-35 AU<sub>550</sub> (Absorbance @ 550 nM) in a minimal salts, glucose medium containing 20 µg/ml kanamycin. Expression of AX-15 protein was induced by addition of IPTG (isopropyl thiogalactoside) to 1.0 mM and the fermentation was continued for an additional 8 hr. AX-15 protein was expressed as insoluble inclusion bodies following IPTG induction. Post-induction, cells were harvested, cell paste concentrated, and buffer exchanged to 20 mM Tris, 1.0 mM DTT, 5.0 mM EDTA, pH 8.5 via AGT 500,000 molecular weight cut off (mwco) hollow fiber diafiltration (ACG Technologies, Inc.). Inclusion bodies were released from the harvested cells by disruption via repeated passage of cooled (0-10°C) cell paste suspension through a continuous flow, high pressure (>8,000 psi) Niro Soavi homogenizer. The homogenate was subjected to two passages through a cooled (4-8°C) continuous flow, high speed (>17,000 x G) Sharples centrifuge (source) to recover inclusion bodies. Recovered inclusion bodies were extracted in 8.0 M guanidine HCl with 1.0 mM DTT. The AX-15 protein/guanidine solution was diluted into 50 mM Tris-HCl, 1.0 mM DTT, 0.05 mM EDTA, pH 8.0-8.3, and diafiltered versus diluent buffer with AGT 5,000 mwco hollow fiber filters (ACG Technologies, Inc.). The resulting solution, containing refolded AX-15, was filtered through a Microgon 0.22 µm hollow fiber filter (ACG Technologies, Inc.) prior to chromatographic purification.

**EXAMPLE 7 - Column Chromatographic Purification of Refolded AX-15**

The filtered AX-15 solution described above was loaded onto a 16.4 L DEAE Sepharose (Pharmacia) column at 10.9 mg/ml resin and washed with 50 L of 50 mM Tris, pH 8.0-8.3, 1.0 mM DTT, and 0.05 mM EDTA buffer. The AX-15 protein was eluted from the column with a 120 mM NaCl step in the same Tris buffer. Eluate exceeding a previously established 280 nM absorbance criteria of 40% maximum A<sub>280</sub>

on the ascending portion of the peak and 20% of maximum  $A_{280}$  on the descending portion of the peak was pooled and either stored frozen (-30°C) or used in the next step of the purification procedure. Pooled eluted AX-15 protein was adjusted to 1.0 M ammonium sulfate by gradual addition of the solid compound, maintaining the 5 pH at 8.0-8.3. The solution was filtered through a 0.22  $\mu$ m Sartorius capsule filter, loaded onto a 12.5 L phenyl Sepharose HP (Pharmacia) column at 8.24 mg/ml of resin, and washed with 55 L of 1.0 M ammonium sulfate in 50 mM Tris buffer with 0.05 mM EDTA, pH 8.0-8.3. Following a 12.0 L wash with 250 mM ammonium sulfate in the same Tris buffer, the AX-15 protein was eluted with a 125 mM 10 ammonium sulfate, Tris buffer wash step. Eluate exceeding previously established 280 nM absorbance criteria of 100% maximum  $A_{280}$  on the ascending portion of the peak and 20% of maximum  $A_{280}$  on the descending portion of the peak was pooled. 15 Eluate was simultaneously diluted 1:4 into 50 mM Tris, pH 8.0 -8.3 buffer without salt to reduce its conductivity. Pooled material was stored frozen (-30°C) or used in the following step. Pooled hydrophobic interaction chromatography (HIC) material was concentrated to 25 L and diafiltered versus 5.0 mM sodium phosphate buffer pH 8.0-8.3 using a 5,000 mwco AGT hollow fiber filter (ACG Technologies, Inc.). The pH was adjusted to 7.0-7.2 immediately prior to sulfonyl propyl fast flow (SP FF) sepharose 20 chromatography by gradual addition of concentrated (85%) phosphoric acid. The pH-adjusted pooled material was loaded onto a 7.7 L SP FF sepharose (Pharmacia) column to 9.0 mg/ml of resin and washed with a minimum of 25 L of 5.0 mM sodium phosphate buffer, pH 7.0. The AX-15 protein was eluted with a 77.0 L step of 25 5.0 mM sodium phosphate, 130 mM NaCl, pH 7.0-7.2. The eluate was simultaneously diluted 1:5 into 10.0 mM sodium phosphate, pH 9.0-9.2 buffer without salt to reduce conductivity and increase pH. Peak material exceeding 20% 30 maximum  $A_{280}$  on the ascending portion of the peak and 20% of the maximum  $A_{280}$  on the descending portion of the peak was pooled. Pooled AX-15 protein was stored frozen (-30°C) or used in the following step. Pooled SP FF sepharose AX-15 protein was concentrated and diafiltered versus 5.0 mM sodium phosphate, pH 8.0 - 8.3 buffer with a 5,000 mwco AGT hollow fiber filter (ACG Technologies, Inc.). The pool (24.66 g) was concentrated to  $\leq$ 5.0 L. Concentrated, diafiltered AX-15 protein

was loaded onto a 50 L S-100 Sephadryl (Pharmacia) sizing column and eluted with 250 L of the same 5.0 mM sodium phosphate buffer, pH 8.0-8.3. Peak material exceeding 40% maximum  $A_{280}$  on the ascending portion of the peak and 40% of the maximum  $A_{280}$  on the descending portion of the peak was pooled. The pooled AX-5 15 protein was filtered through Millipak 0.22  $\mu$ m filters and stored at -80°C prior to dispensing or formulation. The amino acid sequence of AX-15 produced follows. Alternatively, one could produce a sequence which contains a methionine residue before the initial alanine.

Sub B7

10	9	19	29	39	49	59
*	*	*	*	*	*	*
AFTEHSPLT PHRRDLASRS IWLARKIRSD LTALTESYVK HQGLNKNINL DSADGMPVAS						
15	69	79	89	99	109	111
*	*	*	*	*	*	*
TDRWSELTEA ERLQENLQAY RTFHVLLARL LEDQQVHFTP TEGDFHQAIH TLLLQVAFA						
20	129	139	149	159	169	179
*	*	*	*	*	*	*
YQIEELMILL EYKIPRNEAD GMPINVGDGG LFEKKLWGLK VLQELSQWTV RSIHDLRFIS						
25	*					
SHQTG						

METHIONINE+

30	10	20	30	40	50	60
*	*	*	*	*	*	*
MAFTEHSPLT PHRRDLASRS IWLARKIRSD LTALTESYVK HQGLNKNINL DSADGMPVAS						
35	70	80	90	100	110	120
*	*	*	*	*	*	*
TDRWSELTEA ERLQENLQAY RTFHVLLARL LEDQQVHFTP TEGDFHQAIH TLLLQVAFA						
40	130	140	150	160	170	180
*	*	*	*	*	*	*
YQIEELMILL EYKIPRNEAD GMPINVGDGG LFEKKLWGLK VLQELSQWTV RSIHDLRFIS						
45	*					
SHQTG						

Sub B8

EXAMPLE 8 - Use of AX-15 to treat obesity

Animal models:

5

Normal mice

Normal (8 weeks) C57BL/6J mice were obtained from Taconic. The mice received daily subcutaneous injections of vehicle or AX-15. The animals were weighed daily and food intake over 24-hours was determined between days 3 and 4.

10

ob/ob mice

As a result of a single gene mutation on chromosome 6, *ob/ob* mice produce a truncated, non-functional gene product (leptin). These mice are hyperphagic, hyperinsulinemic, and markedly obese.

15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95

C57BL/6J *ob/ob* mice were obtained from Jackson Laboratory and used for experiments at 12-14 weeks of age. The mice received daily subcutaneous injection of vehicle, AX-15, or leptin. Pair-fed group was given the average amount (g) of food consumed by animals treated with AX-15 (0.3 mg/kg). Body weights were obtained daily and food intake over 24-hours was determined between days 3 and 4. On day 8, the animals were sacrificed and carcass analysis was performed.

Diet-induced obesity (DIO) mice

25 AKR/J mice have been shown to be very susceptible to diet induced obesity by increasing body fat content. Although the gene environment(diet) interaction is not completely known regarding this kind of dietary obesity, like in human obesity, the genotype is polygenic.

30 AKR/J mice were obtained from Jackson Laboratory and put on a high fat diet (45% fat; Research Diets) at age 10-12 weeks old. All experiments commenced after 7

weeks on high fat diet. The mice received daily subcutaneous injection of vehicle, AX-15, or leptin. Pair-fed group was given the average amount (g) of food consumed by animals treated with AX-15 (0.1 mg/kg). The animals were weighed daily and food intake over 24-hours was determined between days 3 and 4. On day 8, 5 the animals were sacrificed and sera were obtained for insulin and corticosterone measurements.

## II. Reagents:

10 Recombinant human AX-15 was manufactured as set forth above and leptin was purchased from R & D Systems.

## Results

### Normal mice

AX-15 reduced body weight in normal mice in a dose dependent manner. In 6 days, the animals lost approximately 4%, 11%, and 16% of their body weight at 0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg, respectively (Figure 3).

### ob/ob mice

There was a dose related (0.1 mg/kg - 3 mg/kg) decrease in body weight after AX-15 treatment in *ob/ob* mice (Figure 4). At a dose range of 0.1 mg/kg to 3 mg/kg, there was a 8%-25% reduction of body weight. Animals pair-fed to a specific dose of AX-15 (0.3 mg/kg) showed equivalent loss of body weight as the mice given that dose of 25 AX-15, suggesting food intake is the primary cause of weight reduction.

Leptin was also effective in decreasing body weight in *ob/ob* mice. At 1 mg/kg, leptin decreased body weight 6% in 7 days, following a course almost identical to that of AX-15 given at 0.1 mg/kg (Figure 4).

Carcass analysis showed that there was a significant reduction of total body fat with AX-15 and leptin treatments as well as in pair-fed controls (Table 1). There was a small but non-significant loss of lean mass in all groups as compared to vehicle control animals. Mice receiving only food restriction (pair-fed) had a fat/lean mass ratio no different from vehicle controls, indicating that they lost fat and lean mass equally. However, the AX-15 and leptin treated animals showed preferential loss of body fat as reflected by a decrease in fat/lean mass ratio (Table 1).

### DIO mice

10

AX-15 reduced body weight in DIO mice dose dependently. Within one week, the animals lost approximately 14%, 26%, and 33% of their body weight when given AX-15 at 0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg, respectively (Figure 5). Comparing the effects of the AX-15 treatment and the pair-fed control animals, there was a small but significant difference between the 2 groups, suggesting that decrease food intake was probably the primary, although not the only, cause of weight loss with AX-15 treatment. Indeed, AX-15 significantly attenuated the obesity associated hyperinsulinemia in DIO mice, whereas merely reducing food intake (pair-fed) did not (Figure 6A). In addition, AX-15 did not cause elevation of corticosterone levels, which is a common effect of food restriction (Figure 6B).

15  
20  
25  
30

It is of interest to note that when AX-15 was administered in the same dose range (0.1-1 mg/kg), DIO mice lost more than twice the body weight when compared to normal mice. This higher sensitivity of diet-induced obese animals to AX-15

25 suggests that adiposity may regulate the efficacy of AX-15 such that AX-15 will not cause continuous weight loss after adiposity is normalized.

DIO mice are leptin resistant; no weight loss effect was observed in these animals with daily injection of leptin (1 mg/kg; Figure 5).

30

We conclude as follows:

1. AX-15 caused weight loss in normal mice in a dose dependent manner.

2. AX-15 induced weight loss in *ob/ob* mice in a dose dependent manner. AX-15

5 (0.1 mg/kg) was as effective as leptin (1 mg/kg) in causing weight loss in *ob/ob* mice. Both AX-15 and leptin treatments, but not pair-fed, preferentially reduced total body fat over lean mass.

3. AX-15 caused weight loss in diet-induced obesity mice in a dose dependent

10 manner, whereas leptin was ineffective. AX-15 treatment attenuated obesity associated hyperinsulinemia in DIO mice; this effect was not observed in pair-fed control animals. In addition, AX-15 was more effective in inducing weight loss in DIO mice than normal or *ob/ob* mice. Taken together, our results suggest a specific useful application of AX-15 in the treatment of leptin resistant obesity, such as type II diabetes associated obesity.

4. The effectiveness of AX-15 in reducing body weight in leptin resistant mouse model suggests that AX-15 may also be effective in reducing body weight in obese humans who are resistant or unresponsive to leptin.

Table 1: Results from carcass analysis of *ob/ob* mice

		Fat g	Lean mass g	Fat:Lean Mass
<b>Vehicle</b>	Mean	<b>34.77</b>	<b>4.79</b>	<b>7.26</b>
	sem	1.41	0.24	
<b>Pair-fed to Ax-15 0.3mg/kg</b>		<b>29.36</b>	<b>4.03</b>	<b>7.28</b>
		0.93	0.07	
<b>Ax-15 0.1 mg/kg</b>		<b>30.22</b>	<b>4.38</b>	<b>6.9</b>
		0.59	0.13	
<b>Ax-15 0.3 mg/kg</b>		<b>26.77</b>	<b>4.03</b>	<b>6.64</b>
		0.66	0.08	
<b>Ax-15 1 mg/kg</b>		<b>23.29</b>	<b>3.35</b>	<b>6.95</b>
		0.87	0.12	
<b>Ax-15 3 mg/kg</b>		<b>23</b>	<b>3.5</b>	<b>6.57</b>
		0.53	0.12	
<b>Leptin 1 mg/kg</b>		<b>28.89</b>	<b>4.73</b>	<b>6.11</b>
		0.89	0.1	

EXAMPLE 9 - Intranasal administration of AX-15

As stated above, a model of human obesity is the AKR/J mice which are susceptible to diet-induced obesity (DIO) by an increase in body fat content analogous to 5 humans, and as in human obesity the genotype is polygenic.

Male AKR/J mice (obtained from the Jackson Laboratory, Bar Harbor, ME) were fed a high fat diet (with 45% kcal from fat) starting at 10 weeks of age. At 17 weeks of age, 10 they weighed about 30% more than lean littermates that were fed a normal chow diet. These mice, termed DIO mice, received daily intranasal administration of either vehicle or AX-15 (94  $\mu$ g/mouse in 50  $\mu$ l, which is approximately 1.87 - 2.35 mg/kg); n=10/group. To administer AX-15, the animals were anesthetized briefly with isofluorane, and then a drop (50  $\mu$ l) of either vehicle or AX-15 was placed in their nostrils and inhaled by the animals as they breathed. A group of DIO mice receiving daily subcutaneous injection of AX-15 (0.1 mg/kg) was included as a comparison (n=5). Body weight and 24 hour food intake were recorded daily for 7 days.

A pharmacokinetics profile of AX-15 delivered by the intranasal route was determined in normal female BALB/c mice (100  $\mu$ g/mouse in 50  $\mu$ l, which is equivalent to 3.3 mg/kg; n=3). Sera were obtained from tail bleeds at 0, 0.5, 1, 2, 4, 8 20 & 24 hour intervals after injection. Levels of AX-15 were measured by a two-site ELISA, using a monoclonal antibody to CNTF as capture.

The treatment with AX-15 via intranasal route of delivery was effective in reducing body weight in DIO mice (Figure 7). AX-15 given daily at 94  $\mu$ g/mouse caused an 25 11% weight loss after 7 days. Weight loss was closely correlated to decreased food intake (Figure 8). As expected from the results in Example 8, subcutaneously administered AX-15 at 0.1 mg/kg caused a typical 21% weight loss with concomitant decrease in food consumption (Figure 8).

Pharmacokinetic data showed that when AX-15 was administered by intranasal route at 3.3 mg/kg (100 µg/mouse in 50 µl), a peak serum level of 20 ng/ml (Cmax) was achieved at 0.5 -1 hour (Figure 9). This serum level was well within the efficacious range reached when AX-15 was given by subcutaneous injection (8 -25 ng/ml ).

Thus, AX-15 administered via the intranasal route can be absorbed within the airway and/or through the mucosal lining of the nasal and respiratory tract and achieve serum levels that are in the efficacious range, based upon comparison to levels achieved following subcutaneous injection. AX-15 delivered via an intranasal route was effective in reducing body weight and food intake in DIO mice. Therefore, intranasal delivery can effectively be utilized as a route of administration for AX-15 in treating appropriate disorders such as obesity and diabetes.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.